Q-omics provides the consensus-scored SPSB1 profile across patient tissues and cancer cell-line models. SPSB1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SPSB1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, SPSB1 RNA expression shows 17,284 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, KIRC, and THYM as cancer lineages where SPSB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPSB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPSB1 survival associations across molecular data types. SPSB1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPSB1 RNA expression–survival associations across cancer types. High SPSB1 expression shows unfavorable associations in KIRP, KICH and OV, but favorable associations in LUAD, SCLC and MESO. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for SPSB1 RNA expression.
This table summarizes SPSB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SPSB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPSB1 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, HNSC, KIRP and LUAD. The KIRC box plot shows higher SPSB1 RNA expression in tumor versus normal tissue (log2 FC = +1.399, t-test p < 0.001).
This table shows molecular features associated with SPSB1 in patient tissues and cancer cell lines. In patient samples, SPSB1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPSB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
